KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Debt to Equity: 2016-2025

Historic Debt to Equity for Alnylam Pharmaceuticals (ALNY) over the last 3 years, with Sep 2025 value amounting to $0.52.

  • Alnylam Pharmaceuticals' Debt to Equity was N/A to $0.52 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.52, marking a year-over-year change of. This contributed to the annual value of $1.40 for FY2024, which is N/A change from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' Debt to Equity stood at $0.52, which was up 7.58% from $0.48 recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Debt to Equity registered a high of $1.40 during Q4 2024, and its lowest value of $0.48 during Q2 2025.
  • For the 2-year period, Alnylam Pharmaceuticals' Debt to Equity averaged around $0.86, with its median value being $0.77 (2025).
  • Data for Alnylam Pharmaceuticals' Debt to Equity shows a peak YoY surged of 510.32% (in 2021) over the last 5 years.
  • Over the past 3 years, Alnylam Pharmaceuticals' Debt to Equity (Quarterly) stood at $1.15 in 2021, then followed by $1.40 in 2024, then followed by $0.52 in 2025.
  • Its Debt to Equity stands at $0.52 for Q3 2025, versus $0.48 for Q2 2025 and $1.02 for Q1 2025.